严重喘的临床和经济负担与低血型乙氨基酸细胞计数
John Busby1, Shruti Menon2, Neil Martin3
1Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom.
概括
严重喘患者具有低乙氨基基酸计数往往有不受控制的症状和高口服皮质类固醇的使用,表明需要更好的诊断方法来指导有效治疗.
科学领域:
- 肺部病理学 肺部病理学
- 临床医学 临床医学
- 呼吸道疾病 呼吸道疾病
背景情况:
- 严重的喘与低乙氨基酸细胞数量是一个复杂的表型.
- 这种表型经常被误诊为2型严重喘,导致高剂量皮质类固醇治疗无效.
- 这些患者的持续症状通常与喘无关.
研究的目的:
- 为了表征患有严重喘和低乙酸细胞计数 (<300细胞/μL) 的患者.
- 描述英国医疗保健机构中这些患者的疾病负担和治疗模式.
- 根据血液中乙氨基酸细胞计数 (BEC) 水平分析结果.
主要方法:
- 使用链接的英国数据库 (CPRD Aurum-HES,UKSAR) 的回顾性队列研究.
- 根据基线血中乙氨基酸细胞计数 (BEC ≤150和>150至<300细胞/μL) 分类的患者.
- 对临床特征,治疗方法,结果和医疗资源利用情况的分析.
主要成果:
- 在严重喘患者中,超过70%的患者具有低氨基细胞计数 (≤150细胞/μL).
- 在UKSAR患者中观察到高无控喘率 (45.2%) 和持续口服皮质类固醇使用率 (51.7%).
- 在所有低乙氨基基基群体中,症状控制不良,并且使用了显著的短效β-2激动剂.
结论:
- 严重喘患者的低乙氨基基细胞,特别是那些在专业注册,经历频繁的恶化和不良的症状控制.
- 在这个群体中,高维护性口服皮质类固醇使用增加了皮质类固醇诱导的发病风险.
- 准确评估潜在的病理学对于优化治疗策略在这个患者群体至关重要.
相关概念视频
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
267
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
267
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:26COPD: Management Using Bronchodilators and Corticosteroids
194
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
194